Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Oncopeptides

5,35 SEK

+1,90 %

Mindre end 1K følgere

ONCO

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
Sammenligne
+1,90 %
-7,60 %
+11,57 %
+272,41 %
+264,75 %
+266,64 %
-54,62 %
-95,28 %
-81,48 %

Oncopeptides is a biotech company that develops drugs for difficult-to-treat hematological diseases. The company uses its PDC platform to develop peptide-linked drugs that selectively deliver cytotoxic drugs into cancer cells. The company has drugs in commercialization and several drug candidates under development. Oncopeptide's head office is located in Stockholm.

Læs mere
Markedsværdi
1,46 mia. SEK
Aktieomsætning
4,8 mio. SEK
Omsætning
31,65 mio.
EBIT %
-895,73 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
19.2
2026

Årsrapport '25

13.5
2026

Delårsrapport Q1'26

21.5
2026

Generalforsamling '26

Alle
Selskabspræsentationer
Selskabsmeddelelser
Eksterne analyser
ViserAlle indholdstyper
Selskabsmeddelelse21.11.2025, 07.30

Oncopeptides announces the Nomination Committee

Oncopeptides
Oncopeptides, Capital Markets Update, 2025
Videopræsentation13.11.2025, 08.00

Oncopeptides, Capital Markets Update, 2025

Oncopeptides
Pressemeddelelse11.11.2025, 07.30

Annals of Hematology: Expert consensus supports use of Pepaxti in myeloma

Oncopeptides

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Pressemeddelelse7.11.2025, 07.39

Redeye: Oncopeptides (Q3 Update) - Q/Q Growth Only 5%, but 2026 Looks Promising

Oncopeptides
Oncopeptides, Audiocast, Q3'25
Videopræsentation5.11.2025, 08.00

Oncopeptides, Audiocast, Q3'25

Oncopeptides
Selskabsmeddelelse5.11.2025, 07.00

Oncopeptides publishes Q3 report 2025

Oncopeptides
Pressemeddelelse3.11.2025, 14.30

Research by top universities together with Oncopeptides on NK cell engagers to be presented at ASH

Oncopeptides
Selskabsmeddelelse31.10.2025, 07.30

Number of shares and votes in Oncopeptides

Oncopeptides
Pressemeddelelse29.10.2025, 07.30

Invitation to presentation of the Q3 report 2025

Oncopeptides
Pressemeddelelse22.10.2025, 15.30

Oncopeptides to host Capital Markets Update featuring leading global experts in Multiple Myeloma

Oncopeptides
Pressemeddelelse16.10.2025, 12.00

Journal of Cancer Research and Clinical Oncology: Exceptional long-term responses to Pepaxti

Oncopeptides
Selskabsmeddelelse13.10.2025, 16.45

Oncopeptides issues warrants to fulfil its obligations under loan agreement with EIB

Oncopeptides
Selskabsmeddelelse30.9.2025, 08.00

Number of shares and votes in Oncopeptides

Oncopeptides
Pressemeddelelse25.9.2025, 09.34

BioStock: Video from Oncopeptide's presentation at BioStock Investing in Life Science – From Seed to Success

Oncopeptides
Selskabsmeddelelse17.9.2025, 06.30

Oncopeptides’ rights issue oversubscribed to approximately 157 percent

Oncopeptides
Pressemeddelelse1.9.2025, 06.30

New real-world data confirms efficacy and safety of Pepaxti, presented at IMS Annual Meeting

Oncopeptides
Selskabsmeddelelse28.8.2025, 06.15

Oncopeptides publishes disclosure document regarding rights issue

Oncopeptides
Eksterne analyser27.8.2025, 07.43

Oncopeptides: Targeted oncology with commercial momentum - Edison

Oncopeptides (ONCO) is a Swedish biotech that aims to develop and commercialise therapies for difficult-to-treat cancers, with a focus on haematological diseases. Its lead product, Pepaxti, was approved in Europe in 2022 for relapsed/refractory multiple...

Oncopeptides
Selskabsmeddelelse25.8.2025, 18.40

Oncopeptides enters into additional guarantee commitments, rights issue fully guaranteed

Oncopeptides
Pressemeddelelse22.8.2025, 08.45

Redeye: Oncopeptides Q2 2025 - Funded Until Profitability

Oncopeptides
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.